Medical experts clash over use of 'danger' schizophrenia drug

Caution is killing patients earlier, claims new study by doctors in The Lancet

Excessive caution by drug regulators in Britain and abroad has contributed to the deaths of thousands of patients with severe mental illness, say doctors.

Patients with schizophrenia have been condemned to second-rate treatments, often for years, which are less effective at controlling the illness and preventing suicide because of misplaced anxiety about the safety of the most effective drug, clozapine. The pharmaceutical industry also bears a share of the responsibility for restricting the use of clozapine because it promotes more expensive but less effective drugs which bring it more profit, the doctors say today in The Lancet.

A new study shows that clozapine, always thought to be a dangerous drug, actually cut the death rate among patients with schizophrenia by 26 per cent, compared with the standard treatment. But the finding was challenged by British experts who said the serious side effects linked with clozapine meant patients needed close monitoring and it would always be a drug of last resort.

Worldwide, millions of patients with severe mental illness are treated with antipsychotic drugs to control their delusions and hallucinations. Evidence shows that, on average, they die 25 years earlier than those in the general population, partly because of increased smoking and obesity, but also by suicide.

Professor Jari Tiihonen, of the University of Kuopio, Finland, and colleagues say that the introduction of newer antipsychotics, including clozapine, in the 1990s is widely thought to have increased deaths among patients with schizophrenia. But an analysis of the data shows that, while some drugs were associated with an increased risk, clozapine lowered the risk of dying the most, despite being the drug most closely restricted by the authorities because of safety concerns.

Clozapine can cause agranulocytoisis, which destroys the white blood cells and causes falls in blood pressure, convulsions, diabetes and weight gain. Patients must have regular blood tests while taking it. Professor Tiihonen said: "In all western countries, clozapine is recommended for use only as a second-line drug, after at least two other anti-psychotics have been tried and failed. I would like to see it considered for first line use. Doctors and the [drug regulatory] authorities are too cautious.

"Patients with schizophrenia may suffer delusions and hallucinations for years while doctors try different anti-psychotics before they get to clozapine. They are not active enough in getting patients into remission. They should try clozapine earlier." In a study two years ago in the British Medical Journal, Professor Tiihonen showed that patients were less likely to stop taking taking clozapine than other anti-psychotics, despite its side effects. "Patients are more willing to use it, probably because it is effective," he said.

But Professor Tim Kendall, deputy director of the Royal College of Psychiatrist's research unit, said a major study of clozapine in China showed it was no more effective than the older antipsychotic chlorpromazine. "The evidence for first-line use is not there. Clozapine is associated with a much broader range of side-effects. It seems to have a different effect and works better in people who have tried other drugs which have failed. These findings should be interpreted with real caution."

Les Iversen, professor of pharmacology at the University of Oxford, said: "I cannot agree that clozapine should be the drug of first choice for treating schizophrenia. This is because the adverse side effect of agranulocytosis is serious and can be life-threatening. It occurs in about 2 per cent of patients, and all patients require tedious and costly monitoring, initially weekly, later monthly to detect this side-effect. For this reason, clozapine has become a drug of last resort, and will probably remain so."

Life and Style
ebookNow available in paperback
ebooks
ebookA delicious collection of 50 meaty main courses
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Web Developer - Junior / Mid Weight

    £15000 - £25000 per annum: Recruitment Genius: To support their continued grow...

    Recruitment Genius: Marketing Data Specialist

    £22000 - £25000 per annum: Recruitment Genius: They are the go-to company for ...

    Recruitment Genius: Search Marketing Specialist - PPC / SEO

    Negotiable: Recruitment Genius: This is an opportunity to join the UK's leadin...

    Recruitment Genius: Sales Administrator

    Negotiable: Recruitment Genius: This caravan dealership are currently recruiti...

    Day In a Page

    Greece debt crisis: What happened to democracy when it’s a case of 'Vote Yes or else'?

    'The economic collapse has happened. What is at risk now is democracy...'

    If it doesn’t work in Europe, how is it supposed to work in India or the Middle East, asks Robert Fisk
    The science of swearing: What lies behind the use of four-letter words?

    The science of swearing

    What lies behind the use of four-letter words?
    The Real Stories of Migrant Britain: Clive fled from Zimbabwe - now it won't have him back

    The Real Stories of Migrant Britain

    Clive fled from Zimbabwe - now it won’t have him back
    Africa on the menu: Three foodie friends want to popularise dishes from the continent

    Africa on the menu

    Three foodie friends want to popularise dishes from the hot new continent
    Donna Karan is stepping down after 30 years - so who will fill the DKNY creator's boots?

    Who will fill Donna Karan's boots?

    The designer is stepping down as Chief Designer of DKNY after 30 years. Alexander Fury looks back at the career of 'America's Chanel'
    10 best statement lightbulbs

    10 best statement lightbulbs

    Dare to bare with some out-of-the-ordinary illumination
    Wimbledon 2015: Heather Watson - 'I had Serena's poster on my wall – now I'm playing her'

    Heather Watson: 'I had Serena's poster on my wall – now I'm playing her'

    Briton pumped up for dream meeting with world No 1
    Wimbledon 2015: Nick Bollettieri - It's time for big John Isner to produce the goods to go with his thumping serve

    Nick Bollettieri's Wimbledon Files

    It's time for big John Isner to produce the goods to go with his thumping serve
    Dustin Brown: Who is the tennis player who knocked Rafael Nadal out of Wimbeldon 2015?

    Dustin Brown

    Who is the German player that knocked Nadal out of Wimbeldon 2015?
    Ashes 2015: Damien Martyn - 'England are fired up again, just like in 2005...'

    Damien Martyn: 'England are fired up again, just like in 2005...'

    Australian veteran of that Ashes series, believes the hosts' may become unstoppable if they win the first Test
    Tour de France 2015: Twins Simon and Adam Yates have a mountain to climb during Tour of duty

    Twins have a mountain to climb during Tour of duty

    Yates brothers will target the steepest sections in bid to win a stage in France
    John Palmer: 'Goldfinger' of British crime was murdered, say police

    Murder of the Brink’s-MAT mastermind

    'Goldfinger' of British crime's life ended in a blaze of bullets, say police
    Forget little green men - aliens will look like humans, says Cambridge University evolution expert

    Forget little green men

    Leading evolutionary biologist says aliens will look like humans
    The Real Stories of Migrant Britain: An Algerian scientist adjusts to life working in a kebab shop

    The Real Stories of Migrant Britain

    An Algerian scientist struggles to adjust to her new life working in a Scottish kebab shop
    Bodyworlds museum: Dr Gunther von Hagens has battled legal threats, Parkinson's disease, and the threat of bankruptcy

    Dying dream of Doctor Death

    Dr Gunther von Hagens has battled legal threats, Parkinson's disease, and the threat of bankruptcy